New approaches to treat immune-mediated blood clots from iTTP
Official title: Novel approaches for the treatment of autoimmune disease
Funded at Astero Erado INC · NIH-11323999 · Data updated 2026-11-12
A new therapeutic approach is being developed to help people with immune-mediated thrombotic thrombocytopenic purpura (iTTP), a dangerous blood disorder that can cause life-threatening clots.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Astero Erado INC NIH-funded |
| Lab location | 1 site (College Station, United States) |
| Project start | January 1, 2023 |
| Project end | April 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $1,018,916 |
| NIH project number | 5R44AI174502-03 |
| Project ID | NIH-11323999 on NIH RePORTER |
Who could benefit from this research
✓Could help
Individuals with immune-mediated iTTP who have autoantibodies against ADAMTS13 and require treatment.
✕Less likely to help
Patients without iTTP or without autoantibody-mediated ADAMTS13 deficiency may not benefit.
What this research studies
This project aims to create a novel therapy for iTTP by targeting the autoimmune attack on ADAMTS13, the enzyme that keeps blood clots in check. Researchers plan to develop a treatment that could reduce autoantibody effects and control abnormal von Willebrand factor activity. The work involves preclinical and translational steps to move promising ideas toward patient care, with the goal of improving survival and reducing relapse. If successful, the therapy could offer an alternative to current plasma exchange and broad immunosuppression. The project addresses a high-need condition with significant mortality and morbidity.
Why it matters
Potential benefit: If successful, patients with iTTP may experience fewer relapses and better outcomes with fewer treatment-related side effects.
How similar studies have gone: There is ongoing progress with therapies targeting VWF-platelet interactions, but this specific autoimmune-directed approach is innovative and not yet proven in humans.
Where this research is happening
-
Astero Erado INC
College Station, United States Active
Researchers
- Principal investigator: Kannanganat Sidharthan, Sunil — Astero Erado INC
- Study coordinator: Kannanganat Sidharthan, Sunil
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.